Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Reduction of Initial AHI
- Sponsor
- Medartis AG
- Enrollment
- 29
- Locations
- 1
- Primary Endpoint
- Reduction of initial AHI by ≥20%
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)
Detailed Description
The new OSAS Implant is intended for use in the palate (hard and soft palate/ see picture above) in order to stiffen and stabilize the soft palate, which may reduce the severity of airway obstructions and of snoring in patients suffering from OSA (Obstructive Sleep Apnea). Indications for use of the System include: symptomatic, habitual, social snoring due to palatal flutter or upper airway obstruction primarily caused by the retropalatal obstruction. The System is labeled for use by physicians only. The primary endpoint is the Apnea-Hypopnea-Index (AHI) in the 90 days follow-up. Study hypothesis: Reduction of initial AHI ≥20%
Investigators
Eligibility Criteria
Inclusion Criteria
- •Study patients must meet all of the following inclusion criteria:
- •Socially disturbing snoring with/without obstructive sleep apnea syndrome
- •Predominantly retropalatal obstructions established by ApneaGraph ≥60%, sleep nasendoscopy or successful application of the Velumount palatal device
- •Findings for predominantly retropalatal obstructions in ENT-examination:
- •No tonsils or tonsils grade I - II
- •Normal finding of larynx and tongue base
- •No lingual tonsil hypertrophy
- •ASA (American Society of Anaesthesiology, 1963) criteria I or II
- •Body mass index (BMI) \< 33 kg/m2
- •Age \> 18 yrs
Exclusion Criteria
- •Previous Pillar implants
- •Previous airway surgery other than nasal, adenoid, tonsil or UPPP
- •Presence of other sleep disorders
- •Psychiatric disorders
- •Neurological disorders (e.g. Cerebrovascular injury)
- •Dysmorphia of the cranial skeleton
- •Pregnancy or breastfeeding
- •Known hypersensitivity to nitinol
- •Participation in another clinical study
Outcomes
Primary Outcomes
Reduction of initial AHI by ≥20%
Time Frame: 90days
The primary endpoint is the Apnea-Hypopnea-Index (AHI) at the 90 days follow-up. Study hypothesis: Reduction of initial AHI ≥20%. AHI is measured using cardio-respiratory polygraphy. Two measurements are performed before treatment and at 90 days follow-up in order to reduce effects from night-to-night variability.
Secondary Outcomes
- Reduction of initial snoring index ≥30%(90days)